A Phase IIa, known-treatment without placebo, Multicenter Study of Single-Agent MOR00208, an Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-002659-41

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To assess the antitumor activity of single-agent MOR00208 in adult patients with relapsed or refractory NHL who have received at least one prior therapy containing rituximab as one of the treatments.


Critère d'inclusion

  • Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma